Preeclampsia Risk Assessment

A new, FDA-cleared test enables physicians to assess the risk that a pregnant individual will develop preeclampsia with severe features. Test results, alongside other clinical evaluations, are useful to inform appropriate patient care.

Request More Info

 

 

3017909 Preeclampsia Risk Assessment (sFlt-1/PlGF Ratio)

This test provides valuable information to physicians, facilitating:

  1. Risk assessment for disease progression in patients with hypertension who are hospitalized between 23 + 0/7 and 34 + 6/7 weeks of gestation
  2. Stratification of hospitalized patients based on risk
  3. Management of patients at increased risk of developing preeclampsia with severe features

Why Choose ARUP for Preeclampsia Testing?

badge approved

FDA Cleared

The preeclampsia risk assessment assay offered by ARUP is FDA cleared to evaluate risk in expectant mothers carrying singleton pregnancies between 23 weeks and 0 days and 34 weeks and 6 days of gestation. Positive findings, including an elevated ratio of ≥40 of soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1:PlGF), along with other pertinent markers, enable healthcare providers to initiate enhanced monitoring and timely interventions aimed at mitigating the progression to preeclampsia with severe features.

Blood-Based Biomarkers

Blood-Based Biomarkers

Measurement of blood-based biomarkers sFlt-1 and PlGF allows for a better assessment of preeclampsia risk that will improve outcomes for mothers and their newborns.

Expert Guidance

Expert Guidance

Our medical directors guide test development and are available for consultation on test ordering and results interpretation.

Guideline-Driven Testing

Guideline-Driven Testing

ARUP offers testing options based on guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the International Society for the Study of Hypertension in Pregnancy (ISSHP).

 

Increasing Incidence of Preeclampsia

In the past 20 years, the incidence of preeclampsia has increased by 25%, which makes this condition a prominent contributor to maternal and infant morbidity and mortality.1

Preeclampsia is a multisystem, progressive disorder that is characterized by hypertension and various signs of physiologic dysfunction. Preeclampsia leads to more than 50,000 maternal deaths and 500,000 fetal deaths globally2 and affects 2–8% of all pregnancies.3

Testing for Preeclampsia

Preeclampsia typically occurs after 20 weeks of gestation and may progress rapidly without warning. The preeclampsia risk assessment assay is a valuable tool to aid providers in stratifying risk, determining appropriate clinical management, and improving patient outcomes.

ARUP offers an FDA-cleared immunoassay that measures two placental proteins, serum sFlt-1 and PlGF, and reports them as a ratio. These proteins are key to identifying angiogenic imbalance, which can lead to preeclampsia.

By incorporating testing for angiogenic imbalance, providers can better determine the risk of disease progression in patients with a hypertensive disorder of pregnancy.

Research has specifically shown that if these markers are at a ratio above a certain threshold, the mother would be at high risk for progression to preeclampsia with severe features. If the ratio is below the threshold, there is a low risk of progressing to severe preeclampsia within two weeks."

—Kelly Doyle, PhD, DABCC, FADLM Medical Director of Special Chemistry and Endocrinology

ARUP Laboratory Tests To Assist With Preeclampsia Risk Assessment

3017909 Preeclampsia Risk Assessment (sFlt-1/PlGF Ratio)

Other ARUP Tests To Assess for Preeclampsia

0020025 Creatinine, Serum or Plasma
0050203 Albumin-Creatinine Ratio, Urine
0020479 Protein, Total, Urine
0020007 Aspartate Aminotransferase, Serum or Plasma
0020008 Alanine Aminotransferase, Serum or Plasma
0020032 Bilirubin, Total, Serum or Plasma

Additional Resources

ARUP Consult® Preeclampsia Testing Topic

First-of-Its-Kind, FDA-Cleared Test Uses Blood-Based Biomarkers To Assess Risk for Preeclampsia

FDA Roundup: May 19, 2023

Thermo Fisher Scientific Announces FDA Clearance of Breakthrough Immunoassays to Aid in the Risk Assessment of Preeclampsia

References

  1. Preeclampsia Foundation. What is preeclampsia. Updated May 2023; accessed Jul 2024.
  2. Karrar S, Martingano D, Hong P. Preeclampsia. StatPearls: StatPearls Publishing. Updated Feb 2024; accessed Jul 2024.
  3. Centers for Disease Control and Prevention. High blood pressure during pregnancy. Updated Jun 2024; accessed Aug 2024.